Advancements in modern research allow us to unite projects which include widespread illnesses of the developed countries: atherosclerosis, arterial hypertension, COPD, type 2 diabetes and HIV/AIDS, tuberculosis and other illnesses with chronic inflammation. The underlying basis of diseases involving chronic inflammatory process is the peroxisome proliferator- activating receptors (PPARs).

Peroxisome proliferator-activated receptors (PPARs) were discovered over a decade ago, and were classified as orphan members of the nuclear receptor superfamily. To date, three PPAR subtypes have been discovered and characterized (PPARa). Different PPAR subtypes have been shown to play crucial roles in important conditions such as obesity, diabetes, atherosclerosis, cancer, fertility and aging.
PPARs - key regulators of the lipid and carbohydrates metabolism has recently been the focus of much interest for their possible role in the regulation of inflammatory process and immune response.

Chronic inflammation is frequently associated with the metabolic syndrome. The metabolic syndrome (MS) has emerged as an important cluster of risk factors for atherosclerosis. Common features are central (abdominal) obesity, insulin resistance, hypertension and dyslipidemia which bring us to such disorders as hypertension, heart disease, type 2 diabetes and other illnesses. MS is an increasingly prevalent in industrialized societies (figures from the American Heart Association suggest 20% to 25% of US adults have metabolic syndrome). The presence of the metabolic syndrome is highly prognostic of future cardiovascular events.
Chronic inflammation may represent a triggering factor in the origin of the metabolic syndrome; stimuli such as overnutrition, physical inactivity, and ageing would eventually lead to insulin resistance and diabetes in genetically or metabolically predisposed individuals.

HIV/AIDS and tuberculosis infections are a health epidemic around the world. The development of therapeutic agents that modulate HIV/AIDS and tuberculosis has extended the life expectancy of infected individuals. Unfortunately, with the increased survival of these patients, metabolic complications such as insulin resistance, hyperlipidemia, central adiposity, peripheral lipodystrophy and its ensuing risk of morbidity and mortality has become a major concern. Ligands of PPARs can serve as potential treatment for HIV/AIDS and tuberculosis patients with metabolic complication.

Nation to Nation is dedicated to find most needed resources for our research projects which undoubtedly will benefit humankind.